Sells NexoBrid, an enzyme-based treatment that removes dead tissue from severe burns, to burn centers and hospital burn units, and develops enzymatic treatments for chronic wounds and a topical treatment for basal cell carcinoma.
20-F for FY2025, filed Mar 5, 2026Our flagship product, NexoBrid, is a topically administered biological orphan drug that enzymatically removes eschar while preserving…View ↗
EscharEx® is a bromelain-based, bioactive enzymatic therapy in advanced clinical development for the debridement of chronic and…View ↗
Our pipeline also includes MW005, a topical therapeutic for the treatment of basal cell carcinoma that has demonstrated positive results in…View ↗
The Company generates revenues from sales of its innovative biopharmaceutical product, Nexobrid, to burn centers and hospital burn units in…View ↗
Sells NexoBrid to burn centers and hospital burn units, with product revenue generally tied to delivery. Licensing deals can bring upfront fees, milestone payments and royalties tied to sales; development services generate revenue over the period they are provided.
20-F for FY2025, filed Mar 5, 2026The Company’s revenue-generating arrangements typically include licensing arrangements, which comprise upfront license fees, milestone…View ↗
If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes…View ↗
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, where the license is deemed…View ↗
Revenues from development services are recognized over time, during the period the customer receives and consumes the benefits provided by…View ↗
The Company generates revenues from sales of its innovative biopharmaceutical product, Nexobrid, to burn centers and hospital burn units in…View ↗
Revenues from the sale of goods is recognized in profit or loss at the point in time when the control of the goods is transferred to the…View ↗
$17M
20-F for FY2025, filed Mar 5, 2026
$17M ↗
Burn centers and hospital burn units receive NexoBrid through the company’s commercial organizations and local distributors. The company has local distribution agreements across Europe, Asia-Pacific and the Middle East.
20-F for FY2025, filed Mar 5, 2026
Shrinking. Revenue fell 29% in 4 years, from $23.8M in FY2021 to $17M in FY2025, about 8% a year.
Competes with Smith & Nephew
20-F for FY2025, filed Mar 5, 2026In addition, we face competition from the current SOC. The current SOC for eschar removal in severe burns is surgery, where eschar removal…View ↗
Loading...